The objective of this study was to analyze if repetitive administration of antenatal @entity230 (ANS) had an adverse impact on neonatal outcome at hospital discharge in premature @entity1 . We used a retrospective analysis of 306 @entity1 of gestational age (GA) < or = 34 weeks born between January 1997 and June 1999. A detailed review of maternal and neonatal charts was done. Seventy-one percent (216/306) received ANS. While there was no difference in birth weight (1.37 +/- 0.04 versus 1.49 +/- 0.06 kg; p = 0.09), @entity1 receiving ANS were of lesser GA (29.5 +/- 0.2 versus 30.5 +/- 0.4 weeks; p = 0.02). More babies who received ANS had clinical evidence of @entity354 ( @entity354 ) [59/216 (27%) versus 11/90 (12%); p = 0.007]. After correcting for GA, @entity1 receiving ANS were less likely to need surfactant (p = 0.03) and more likely to be diagnosed with clinical @entity354 (p = 0.02). Ninety (29%) @entity1 received no ANS, 47 (15%) received a suboptimal course, 112 (37%) @entity1 received 1 course of ANS, and 57 (19%) @entity1 received > or = 2 courses. There was a significant increase in the incidence of @entity354 with increasing courses of ANS: 0 course 11/90 (12%), suboptimal 12/47 (26%), 1 course 28/112 (25%), 2 or more courses 18/57 (32%); p = 0.006, linear trend. The increased incidence of @entity354 (p = 0.01) still held true among @entity1 who had @entity354 confirmed by a pH-probe study. Use of ANS is associated with a significantly decreased need for surfactant; however, there is an increased incidence of @entity354 .

Antenatal steroid use is associated with increased XXXX in neonates.

@entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1 :: ('9606', 'Species') :: ['infants'] @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophageal reflux', 'GER']
@entity354 :: (MESH:D005764,Disease) :: ['gastroesophageal reflux']
